2017-05-04 12:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2017
Message from the CEO IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following...
2017-04-06 20:00
Infant Bacterial Therapeutics AB (publ) Annual Report for 2016 has now been published
Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com. A physical copy of the Annual...
2017-04-05 20:00
Annual General Meeting in Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset...
2017-03-10 13:00
Infant Bacterial Therapeutics AB (publ), (IBT) has been approved for listing on Nasdaq First North's Premier segment.
Infant Bacterial Therapeutics AB (publ) ("IBT"), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First...
2017-03-01 15:00
IBT to present at Bio-Europe Spring 2017
Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants...
2017-02-14 08:00
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 - December 31 2016
Message from the CEO "During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA. The last...
2017-01-24 16:51
Last patient enrolled in IBT's Phase 2 study
Infant Bacterial Therapeutics AB (publ) ("IBT") announces that the last premature infant has now been enrolled and recruitment to the Phase 2...
2016-12-15 09:00
IBT to present at 9th Annual Biotech Showcase 2017
Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants...
Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants...
2016-11-21 09:00
Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
"We are very pleased that we now have 90 of the 120 premature babies recruited and that the study is progressing according to plan. This is another...